Pentraxin-3 as a poor marker of fibrosis in metabolic dysfunction-associated steatotic liver disease among older adults: findings from the PolSenior2 substudy
IntroductionThe study aimed to assess the relationship between plasma pentraxin 3 (PTX-3) levels and the potential diagnosis of fibrosis in metabolic dysfunction-associated steatohepatitis (MASH) in older adults. This was assessed using the Fibrosis-4 index (FIB-4), NAFLD fibrosis score (NFS), and H...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-02-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2025.1445973/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849722999810293760 |
|---|---|
| author | Aleksander Jerzy Owczarek Joanna Musialik Adrian Stefański Małgorzata Mossakowska Katarzyna Zięba Andrzej Więcek Jerzy Chudek Magdalena Olszanecka-Glinianowicz |
| author_facet | Aleksander Jerzy Owczarek Joanna Musialik Adrian Stefański Małgorzata Mossakowska Katarzyna Zięba Andrzej Więcek Jerzy Chudek Magdalena Olszanecka-Glinianowicz |
| author_sort | Aleksander Jerzy Owczarek |
| collection | DOAJ |
| description | IntroductionThe study aimed to assess the relationship between plasma pentraxin 3 (PTX-3) levels and the potential diagnosis of fibrosis in metabolic dysfunction-associated steatohepatitis (MASH) in older adults. This was assessed using the Fibrosis-4 index (FIB-4), NAFLD fibrosis score (NFS), and Hepamet fibrosis score (HFS).Materials and methodsThe subanalysis included 2,397 older adults (aged 60 years and older) from the population-based PolSenior2 study, all of whom had risk factors for metabolic dysfunction-associated steatotic liver disease (MASLD) and underwent PTX-3 assessment. The participants were divided into two subgroups according to the FIB-4 values (≤2.67 and > 2.67), three subgroups according to the NFS values (< −1.455, −1.455, and 0.675, and > 0.675), and three subgroups according to the HFS values (< 0.12, 0.12 and 0.47 and > 0.47).ResultsThe empirical cutoff points for PTX-3 levels as a potential marker of liver fibrosis were assessed separately for women and men. In women, the cutoff points for PTX-3 levels based on ROC curve analyses ranged from 1.96 to 2.30 ng/mL (an AUC ranging from 0.596 to 0.643, sensitivity between 39.1 and 61.7%, and specificity between 56.1 and 79.6%). In men, a significant cutoff point was established for FIB-4 (an AUC of 0.549, sensitivity of 39.4%, and specificity of 69.6%). Overall, the accuracy was poor.ConclusionOur study suggests that plasma PTX-3 levels are not sensitive enough to be used as a non-specific marker of liver fibrosis in older adults. |
| format | Article |
| id | doaj-art-66738bdd3a3f47779dc80b7cdea7e423 |
| institution | DOAJ |
| issn | 2296-858X |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj-art-66738bdd3a3f47779dc80b7cdea7e4232025-08-20T03:11:10ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2025-02-011210.3389/fmed.2025.14459731445973Pentraxin-3 as a poor marker of fibrosis in metabolic dysfunction-associated steatotic liver disease among older adults: findings from the PolSenior2 substudyAleksander Jerzy Owczarek0Joanna Musialik1Adrian Stefański2Małgorzata Mossakowska3Katarzyna Zięba4Andrzej Więcek5Jerzy Chudek6Magdalena Olszanecka-Glinianowicz7Health Promotion and Obesity Management Unit, Department of Pathophysiology, Faculty of Medical Sciences in Katowice, Medical University of Silesia in Katowice, Katowice, PolandDepartment of Nephrology, Transplantology and Internal Medicine, Faculty of Medical Sciences in Katowice, Medical University of Silesia in Katowice, Katowice, PolandDepartment of Preventive Medicine and Education, Faculty of Medical Science, Medical University of Gdańsk, Gdańsk, PolandStudy on Aging and Longevity, International Institute of Molecular and Cell Biology, Warsaw, PolandDepartment of Internal Medicine and Oncological Chemotherapy, Faculty of Medical Sciences in Katowice, Medical University of Silesia in Katowice, Katowice, PolandDepartment of Nephrology, Transplantology and Internal Medicine, Faculty of Medical Sciences in Katowice, Medical University of Silesia in Katowice, Katowice, PolandDepartment of Internal Medicine and Oncological Chemotherapy, Faculty of Medical Sciences in Katowice, Medical University of Silesia in Katowice, Katowice, PolandHealth Promotion and Obesity Management Unit, Department of Pathophysiology, Faculty of Medical Sciences in Katowice, Medical University of Silesia in Katowice, Katowice, PolandIntroductionThe study aimed to assess the relationship between plasma pentraxin 3 (PTX-3) levels and the potential diagnosis of fibrosis in metabolic dysfunction-associated steatohepatitis (MASH) in older adults. This was assessed using the Fibrosis-4 index (FIB-4), NAFLD fibrosis score (NFS), and Hepamet fibrosis score (HFS).Materials and methodsThe subanalysis included 2,397 older adults (aged 60 years and older) from the population-based PolSenior2 study, all of whom had risk factors for metabolic dysfunction-associated steatotic liver disease (MASLD) and underwent PTX-3 assessment. The participants were divided into two subgroups according to the FIB-4 values (≤2.67 and > 2.67), three subgroups according to the NFS values (< −1.455, −1.455, and 0.675, and > 0.675), and three subgroups according to the HFS values (< 0.12, 0.12 and 0.47 and > 0.47).ResultsThe empirical cutoff points for PTX-3 levels as a potential marker of liver fibrosis were assessed separately for women and men. In women, the cutoff points for PTX-3 levels based on ROC curve analyses ranged from 1.96 to 2.30 ng/mL (an AUC ranging from 0.596 to 0.643, sensitivity between 39.1 and 61.7%, and specificity between 56.1 and 79.6%). In men, a significant cutoff point was established for FIB-4 (an AUC of 0.549, sensitivity of 39.4%, and specificity of 69.6%). Overall, the accuracy was poor.ConclusionOur study suggests that plasma PTX-3 levels are not sensitive enough to be used as a non-specific marker of liver fibrosis in older adults.https://www.frontiersin.org/articles/10.3389/fmed.2025.1445973/fullPTX-3FIB-4MASLDfibrosisNASHthe elderly population |
| spellingShingle | Aleksander Jerzy Owczarek Joanna Musialik Adrian Stefański Małgorzata Mossakowska Katarzyna Zięba Andrzej Więcek Jerzy Chudek Magdalena Olszanecka-Glinianowicz Pentraxin-3 as a poor marker of fibrosis in metabolic dysfunction-associated steatotic liver disease among older adults: findings from the PolSenior2 substudy Frontiers in Medicine PTX-3 FIB-4 MASLD fibrosis NASH the elderly population |
| title | Pentraxin-3 as a poor marker of fibrosis in metabolic dysfunction-associated steatotic liver disease among older adults: findings from the PolSenior2 substudy |
| title_full | Pentraxin-3 as a poor marker of fibrosis in metabolic dysfunction-associated steatotic liver disease among older adults: findings from the PolSenior2 substudy |
| title_fullStr | Pentraxin-3 as a poor marker of fibrosis in metabolic dysfunction-associated steatotic liver disease among older adults: findings from the PolSenior2 substudy |
| title_full_unstemmed | Pentraxin-3 as a poor marker of fibrosis in metabolic dysfunction-associated steatotic liver disease among older adults: findings from the PolSenior2 substudy |
| title_short | Pentraxin-3 as a poor marker of fibrosis in metabolic dysfunction-associated steatotic liver disease among older adults: findings from the PolSenior2 substudy |
| title_sort | pentraxin 3 as a poor marker of fibrosis in metabolic dysfunction associated steatotic liver disease among older adults findings from the polsenior2 substudy |
| topic | PTX-3 FIB-4 MASLD fibrosis NASH the elderly population |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2025.1445973/full |
| work_keys_str_mv | AT aleksanderjerzyowczarek pentraxin3asapoormarkeroffibrosisinmetabolicdysfunctionassociatedsteatoticliverdiseaseamongolderadultsfindingsfromthepolsenior2substudy AT joannamusialik pentraxin3asapoormarkeroffibrosisinmetabolicdysfunctionassociatedsteatoticliverdiseaseamongolderadultsfindingsfromthepolsenior2substudy AT adrianstefanski pentraxin3asapoormarkeroffibrosisinmetabolicdysfunctionassociatedsteatoticliverdiseaseamongolderadultsfindingsfromthepolsenior2substudy AT małgorzatamossakowska pentraxin3asapoormarkeroffibrosisinmetabolicdysfunctionassociatedsteatoticliverdiseaseamongolderadultsfindingsfromthepolsenior2substudy AT katarzynazieba pentraxin3asapoormarkeroffibrosisinmetabolicdysfunctionassociatedsteatoticliverdiseaseamongolderadultsfindingsfromthepolsenior2substudy AT andrzejwiecek pentraxin3asapoormarkeroffibrosisinmetabolicdysfunctionassociatedsteatoticliverdiseaseamongolderadultsfindingsfromthepolsenior2substudy AT jerzychudek pentraxin3asapoormarkeroffibrosisinmetabolicdysfunctionassociatedsteatoticliverdiseaseamongolderadultsfindingsfromthepolsenior2substudy AT magdalenaolszaneckaglinianowicz pentraxin3asapoormarkeroffibrosisinmetabolicdysfunctionassociatedsteatoticliverdiseaseamongolderadultsfindingsfromthepolsenior2substudy |